NDRA net incomeQ2 2026$159.9K
NDRA net income was $159.9K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.23M a year earlier. For the full fiscal 2025 it was -$7.03M, compared with -$11.51M in fiscal 2024.
ENDRA Life Sciences Inc. (NDRA) financials
For the twelve months ended Jun 30, 2026, ENDRA Life Sciences Inc. reported -$5.92M of net income.
- Net income, TTM
- -$5.92M
- Cash
- $1.74M
- Market cap
- $7.1M
FY2016FY2020
FY2016FY2025
FY2017FY2025
NDRA revenue and earnings growth
NDRA EPSQ2 2026$0.06
NDRA diluted EPS was $0.06 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$8.93.
NDRA free cash flowQ4 2025-$1.61M
NDRA free cash flow was -$1.61M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$1.52M a year earlier. For the full fiscal 2025 it was -$5.20M, compared with -$7.42M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $0 | $0 | $6.2K | $351.6K | $515.6K |
| Cost of revenue | - | - | - | - | - | $0 | $0 | $0 | $172.8K | - |
| Gross profit | - | - | - | - | - | $0 | $0 | $6.2K | $178.8K | $279.7K |
| Research and development | $1.85M | $3.19M | $5.00M | $6.55M | $5.48M | $5.92M | $6.57M | $4.72M | $1.93M | $495.4K |
| Selling, general and admin | $3.72M | $7.06M | $4.70M | $5.17M | $4.94M | $5.00M | $3.86M | $3.75M | $2.75M | $1.54M |
| Operating income | -$5.76M | -$10.82M | -$10.52M | -$13.16M | -$11.50M | -$11.50M | -$10.84M | -$9.02M | -$4.63M | -$1.79M |
| Interest expense | - | - | - | - | - | - | - | - | $42.6K | $72.0K |
| Pre-tax income | -$7.03M | -$11.51M | -$10.06M | -$13.18M | -$11.23M | -$11.73M | -$13.31M | -$9.80M | -$5.38M | -$2.78M |
| Income tax | - | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7.03M | -$11.51M | -$10.06M | -$13.18M | -$11.23M | -$11.73M | -$13.31M | -$9.80M | -$5.38M | -$2.78M |
| EPS, basic | -$8.93 | -$56.94 | - | -$4.56 | -$5.55 | -$0.63 | -$2.34 | -$2.17 | -$1.95 | -$3.84 |
| EPS, diluted | -$8.93 | -$56.94 | -$2766.85 | - | - | -$0.63 | -$2.34 | -$2.17 | -$1.95 | -$3.84 |
| Diluted shares | 787,020 | 202,106 | 3,636 | - | - | 19.2M | 7.5M | 4.5M | 2.8M | 723,283 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $762.4K | $3.23M | $2.83M | $4.89M | $9.46M | $7.23M | $6.17M | $6.47M | $5.60M | $145.0K |
| Receivables | - | - | - | - | - | - | - | $0 | $6.8K | $0 |
| Inventory | $0 | $0 | $2.62M | $2.64M | $1.28M | $589.6K | $113.4K | $59.4K | $191.7K | $40.1K |
| Current assets | $968.0K | $3.43M | $3.03M | $5.38M | $12.09M | $8.21M | $6.54M | $6.95M | $5.88M | $195.6K |
| Total assets | $3.85M | $4.45M | $6.75M | $9.27M | $12.87M | $8.76M | $7.18M | $7.22M | $6.12M | $490.8K |
| Current liabilities | $751.0K | $605.2K | $903.1K | $1.70M | $1.54M | $986.7K | $2.07M | $974.6K | $848.2K | $1.38M |
| Short-term debt | - | $0 | $28.5K | $28.5K | - | - | - | - | - | - |
| Total debt | - | $0 | $0 | $0 | $546.6K | - | - | - | - | - |
| Total liabilities | $1.59M | $1.89M | $1.10M | $2.07M | $2.09M | $1.60M | $2.42M | $974.6K | $848.2K | $1.38M |
| Shareholders' equity | $2.26M | $2.56M | $5.66M | $7.20M | $10.78M | $7.17M | $4.76M | $6.25M | $5.28M | -$893.8K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.18M | -$7.40M | -$9.55M | -$12.77M | -$11.12M | -$10.75M | -$8.59M | -$7.70M | -$3.30M | -$1.32M |
| Capital expenditures | $17.3K | $16.0K | $33.9K | $202.6K | $45.0K | $75.3K | $43.6K | $100.0K | $7.9K | - |
| Free cash flow | -$5.20M | -$7.42M | -$9.58M | -$12.97M | -$11.17M | -$10.82M | -$8.63M | -$7.80M | -$3.31M | - |
| Investing cash flow | -$3.02M | -$12.8K | -$24.7K | -$202.6K | -$45.0K | -$75.3K | -$43.6K | -$100.0K | -$7.9K | $0 |
| Financing cash flow | $5.73M | $7.81M | $7.52M | $8.40M | $13.40M | $11.88M | $8.34M | $8.67M | $8.77M | $1.44M |
| Stock-based compensation | $329.4K | $571.9K | $996.4K | $1.20M | $1.44M | $2.10M | - | - | - | - |
| Depreciation and amortization | $44.0K | $46.5K | $123.7K | $96.7K | $116.2K | $99.3K | $80.6K | $68.3K | $61.5K | $64.9K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | -100.0% | -98.2% | -31.8% | - |
| Gross margin | - | - | - | - | - | - | - | 100.0% | 50.9% | 54.3% |
| Operating margin | - | - | - | - | - | - | - | -146080.5% | -1315.6% | -347.5% |
| Net margin | - | - | - | - | - | - | - | -158669.6% | -1529.2% | -538.3% |
| Free cash flow margin | - | - | - | - | - | - | - | -126376.4% | -941.0% | - |
| Return on equity | -310.9% | -449.5% | -177.8% | -182.9% | -104.1% | -163.6% | -279.5% | -156.8% | -101.9% | - |
| Return on assets | -182.4% | -258.5% | -148.9% | -142.1% | -87.2% | -133.8% | -185.4% | -135.6% | -87.8% | -565.5% |
| Current ratio | 1.29 | 5.67 | 3.36 | 3.16 | 7.83 | 8.32 | 3.15 | 7.13 | 6.93 | 0.14 |
| Debt to equity | - | 0.00 | 0.00 | 0.00 | 0.05 | - | - | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $233.7K | $776.4K | $508.1K | $432.1K | $381.1K | $528.7K | $638.0K | $794.4K | $716.4K | $1.04M | $579.4K | $1.63M |
| Selling, general and admin | $1.24M | $1.39M | $1.11M | $893.3K | $851.2K | $871.6K | $3.57M | $631.4K | $1.35M | $1.50M | $730.6K | $1.25M |
| Operating income | -$1.48M | -$2.17M | -$1.62M | -$1.37M | -$1.30M | -$1.47M | -$4.30M | -$1.51M | -$2.23M | -$2.78M | -$1.46M | -$3.13M |
| Pre-tax income | $159.9K | -$1.31M | -$3.17M | -$1.60M | -$1.23M | -$1.04M | -$4.15M | -$2.35M | -$2.23M | -$2.78M | -$1.46M | -$3.10M |
| Income tax | - | - | - | - | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $159.9K | -$1.31M | -$3.17M | -$1.60M | -$1.23M | -$1.04M | -$4.15M | -$2.35M | -$2.23M | -$2.78M | -$1.46M | -$3.10M |
| EPS, basic | $0.12 | -$1.09 | - | -$2.10 | -$1.71 | -$1.86 | - | -$9.54 | - | - | - | - |
| EPS, diluted | $0.06 | -$1.09 | - | -$2.10 | -$1.71 | -$1.86 | - | -$9.54 | - | - | - | - |
| Diluted shares | 2.5M | 1.2M | - | 761,218 | 717,107 | 557,582 | - | 246,816 | - | - | - | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.74M | $356.5K | $762.4K | $794.0K | $1.81M | $2.06M | $3.23M | $4.75M | $6.40M | $1.13M | $2.83M | $3.33M |
| Inventory | - | - | $0 | $0 | $0 | $0 | $0 | $2.71M | $2.71M | $2.71M | $2.62M | $2.76M |
| Current assets | $5.59M | $536.7K | $968.0K | $1.05M | $1.85M | $2.18M | $3.43M | $4.96M | $6.71M | $1.27M | $3.03M | $6.40M |
| Total assets | $7.94M | $3.44M | $3.85M | $1.96M | $2.81M | $3.17M | $4.45M | $8.38M | $10.44M | $5.06M | $6.75M | $7.60M |
| Current liabilities | $786.6K | $835.4K | $751.0K | $800.3K | $576.6K | $565.8K | $605.2K | $814.0K | $1.35M | $1.22M | $903.1K | $2.17M |
| Short-term debt | - | - | - | - | - | - | $0 | $0 | $0 | $0 | $28.5K | $28.5K |
| Total debt | - | - | - | - | - | - | $0 | - | - | $0 | $0 | - |
| Total liabilities | $1.63M | $1.65M | $1.59M | $1.79M | $1.33M | $1.42M | $1.89M | $1.77M | $1.45M | $1.36M | $1.10M | $2.41M |
| Shareholders' equity | $6.31M | $1.79M | $2.26M | $171.4K | $1.47M | $1.75M | $2.56M | $6.60M | $8.99M | $3.70M | $5.66M | $5.20M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$927.6K | -$1.12M | -$1.61M | -$1.16M | -$1.11M | -$1.29M | -$1.52M | -$1.66M | -$2.08M | -$2.14M | -$2.17M | -$2.60M |
| Capital expenditures | - | - | $0 | $0 | $0 | $17.3K | $0 | $0 | -$11.0K | $27.0K | $6.9K | $0 |
| Free cash flow | - | - | -$1.61M | -$1.16M | -$1.11M | -$1.31M | -$1.52M | -$1.66M | -$2.09M | -$2.17M | -$2.18M | -$2.60M |
| Investing cash flow | $2.22M | $450.0K | -$3.00M | $0 | $0 | -$17.3K | $0 | $0 | $11.0K | -$23.8K | $2.3K | $0 |
| Financing cash flow | $3.89M | $263.7K | $4.58M | $149.5K | $857.4K | $145.8K | $0 | $1.7K | $7.34M | $468.9K | $1.67M | $1.11M |
| Stock-based compensation | $541.9K | $574.5K | $12.9K | $144.7K | $39.5K | $83.0K | $104.7K | -$36.8K | $186.6K | $317.5K | $250.6K | $252.7K |
| Depreciation and amortization | $8.2K | $9.5K | $10.1K | $10.8K | $9.4K | $13.8K | $11.0K | $11.5K | $8.7K | $15.3K | $21.9K | $32.1K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 7.10 | 0.64 | 1.29 | 1.31 | 3.21 | 3.85 | 5.67 | 6.10 | 4.97 | 1.04 | 3.36 | 2.95 |
| Debt to equity | - | - | - | - | - | - | 0.00 | - | - | 0.00 | 0.00 | - |
Source: XBRL data ENDRA Life Sciences Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
NDRA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NDRA | - | - | -$5.92M | - | $7.1M |
| MDT | $37.54B | +9.8% | $5.24B | 14.0% | $130.22B |
| LIVN | $1.51B | +11.7% | $196.06M | 13.0% | $4.96B |
| ITGR | $1.83B | -0.3% | $103.70M | 5.7% | $4.30B |
| TMDX | $727.65M | +28.5% | $144.45M | 19.9% | $3.06B |
| AXGN | $266.93M | +24.3% | -$31.92M | -12.0% | $2.99B |
| CNMD | $1.37B | +1.6% | $73.43M | 5.4% | $1.53B |
| CBLL | $108.72M | +31.3% | -$73.88M | -68.0% | $1.03B |
| INMD | $370.50M | -6.2% | $93.83M | 25.3% | $765.9M |
NDRA FAQ
4 questionsIs NDRA profitable?
No. ENDRA Life Sciences Inc. reported a net loss of $5.92M for the twelve months ended Jun 30, 2026.How much cash and debt does NDRA have?
ENDRA Life Sciences Inc. reported $1.74M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did NDRA last report financial results?
The latest statements here come from ENDRA Life Sciences Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this NDRA financial data come from?
Quantisnow builds these statements from the structured XBRL data ENDRA Life Sciences Inc. files with the SEC. It is provided for information only and is not investment advice.